Literature DB >> 30875132

Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease.

J W Frew1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30875132      PMCID： PMC6660414          DOI： 10.1111/jdv.15572

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  9 in total

1.  Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.

Authors:  C C Zouboulis; T Tzellos; A Kyrgidis; G B E Jemec; F G Bechara; E J Giamarellos-Bourboulis; J R Ingram; T Kanni; I Karagiannidis; A Martorell; Ł Matusiak; A Pinter; E P Prens; D Presser; S Schneider-Burrus; E von Stebut; J C Szepietowski; H H van der Zee; S M Wilden; R Sabat
Journal:  Br J Dermatol       Date:  2017-10-30       Impact factor: 9.302

2.  Treatment of hidradenitis suppurativa with etanercept injection.

Authors:  David R Adams; Jessica A Yankura; Anneli C Fogelberg; Bryan E Anderson
Journal:  Arch Dermatol       Date:  2010-05

3.  Guselkumab in the treatment of severe hidradenitis suppurativa.

Authors:  M Kovacs; M Podda
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-02-18       Impact factor: 6.166

4.  Low and high body mass index in hidradenitis suppurativa patients-different subtypes?

Authors:  P Theut Riis; D M Saunte; F Benhadou; V Del Marmol; P Guillem; M El-Domyati; H Abdel-Wahab; C Antoniou; C Dessinioti; M A Gürer; B Beksaç; J C Szepietowski; L Matusiak; L Emtestam; J Lapins; H Riad; N Doss; A F Massa; I Hamzavi; C Nicholson; M Dolenc-Voljc; K H Kim; J Ohn; C C Zouboulis; I Karagiannidis; Z B Mokos; P Durinec; G B E Jemec
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-10-10       Impact factor: 6.166

5.  MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.

Authors:  Theodora Kanni; Maria Argyropoulou; Themistoklis Spyridopoulos; Aikaterini Pistiki; Michael Stecher; Charles A Dinarello; John Simard; Evangelos J Giamarellos-Bourboulis
Journal:  J Invest Dermatol       Date:  2017-11-10       Impact factor: 8.551

6.  Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.

Authors:  Allard R J V Vossen; Martijn B A van Doorn; Hessel H van der Zee; Errol P Prens
Journal:  J Am Acad Dermatol       Date:  2018-07-03       Impact factor: 11.527

7.  Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.

Authors:  Vassiliki Tzanetakou; Theodora Kanni; Sophia Giatrakou; Alexandros Katoulis; Evangelia Papadavid; Mihai G Netea; Charles A Dinarello; Jos W M van der Meer; Dimitrios Rigopoulos; Evangelos J Giamarellos-Bourboulis
Journal:  JAMA Dermatol       Date:  2016-01       Impact factor: 10.282

8.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Authors:  Alexa B Kimball; Martin M Okun; David A Williams; Alice B Gottlieb; Kim A Papp; Christos C Zouboulis; April W Armstrong; Francisco Kerdel; Michael H Gold; Seth B Forman; Neil J Korman; Evangelos J Giamarellos-Bourboulis; Jeffrey J Crowley; Charles Lynde; Ziad Reguiai; Errol-Prospero Prens; Eihab Alwawi; Nael M Mostafa; Brett Pinsky; Murali Sundaram; Yihua Gu; Dawn M Carlson; Gregor B E Jemec
Journal:  N Engl J Med       Date:  2016-08-04       Impact factor: 91.245

9.  A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa.

Authors:  John W Frew; Jason E Hawkes; James G Krueger
Journal:  F1000Res       Date:  2018-12-13
  9 in total
  1 in total

1.  Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.

Authors:  John W Frew; Caroline S Jiang; Neha Singh; David Grand; Kristina Navrazhina; Roger Vaughan; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2019-12-24       Impact factor: 11.527
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.